| Literature DB >> 33042600 |
Terrance James Lynn1, Jordan Erik Olson1.
Abstract
BACKGROUND: To improve communication between clinical providers and the laboratory, we recently implemented secure text messaging for our critical value notifications. This was done to communicate laboratory critical values (CV) to providers faster so changes to patient care could be done faster. Our previous method of communicating CV to providers was paging and relied on a call back to receive the critical value.Entities:
Keywords: Critical value turnaround time; critical values; laboratory; secure text messaging; smartphone technology
Year: 2020 PMID: 33042600 PMCID: PMC7518196 DOI: 10.4103/jpi.jpi_19_20
Source DB: PubMed Journal: J Pathol Inform
Regulatory considerations for implementation of a CV system
| Regulatory Considerations of a CV System | ||
|---|---|---|
| Questions to Compare | CAP | TJC |
| 1.) Patient Name | ||
| 2.) Patient MRN | 1.) Patient Name | |
| 3.) Test Name | 2.) Patient MRN | |
| What to communicate? | 4.) Test Result | 3.) Test Name |
| 5.) Date of Result | 4.) Test Result | |
| 6.) Time of Result | ||
| How to Communicate? | Phone call or electronic | Telephone or verbal |
| Confirmation of result sent to Intended Recipient? | Yes, required confirmation of intended recipient (first and last name) | Yes, required confirmation of “whom” results were reported to |
| Readback required? | No, not required | Yes |
| Electronic transmission of result is acceptable? | Acceptable | Acceptable |
| Evidence of Compliance? | Records demonstrating the above and documentation of responsible laboratory personnel reporting result | Records demonstrating above |
| Guideline | 1.) CAP COM.30000 | 1.) Standard International patient safety goal 2 (IPSG.2) |
List of critical values for Geisinger
| Chemistry critical values | |||||
|---|---|---|---|---|---|
| Test Name | Lower limit | Upper limit | Test Name | Lower limit | Upper limit |
| Acetaminophen | >150 ug/mL | pO2 (Arterial) | ≤50 mmHg | ||
| Ammonia | >80 umol/L | Potassium | <2.5 mmol/L | >6 mmol/L | |
| Total billirubin (<1 year old) | >16 mg/dL | Salicylate | >40 mg/dL | ||
| BUN | >100 mg/dL | Sodium | <120 mmol/L | >155 mmol/dL | |
| Caffeine | >50 ug/mL | Tacrolimus (FK506) | ≥15 ng/mL | ||
| Calcium ionized | <0.76 mmol/L | >1.59 mmol/L | Theophylline | >21 ug/mL | |
| Carbamazepine | >15 ug/mL | Tobramycin (peak/random) | >12 ug/mL | ||
| CO2 (serum/plasma) | <12 mmol/L | >40 mmol/L | Tobramycin (trough) | >4 ug/mL | |
| Carboxyhemoglobin | >9% | Troponin T | >100 ng/mL | ||
| Chloride | <70 mmol/L | >130 mmol/L | Valproic acid | >121 ug/mL | |
| CK-MB | ≥9 ng/mL | Vancomycin (peak/random) | >50 ug/mL | ||
| Creatinine | >10 mg/dL | Vancomycin (trough) | >25 ug/mL | ||
| Cyclosproine | >800 ng/mL | Coagulation | |||
| Digoxin | ≥2.5 ng/mL | INR | >4.99 | ||
| Gentamicin in Peak | >12 ug/mL | Activated partial thromboplastin time | >120 seconds | ||
| Gentamicin in Random | >12 ug/mL | Fibrinogen | <60 mg/dL | ||
| Gentamicin in Trough | >4 ug/mL | Heparin level (unfractionated) | >0.99 IU/mL | ||
| Glucose (includes tolerance) | <45 mg/dL | >200 mg/dL | Tobramycin (peak/random) | >12 ug/mL | |
| Glucose (CSF) | <40 mg/dL | >200 mg/dL | Tobramycin (trough) | >4 ug/mL | |
| Lactate | >4 mmol/dL | Troponin T | >100 ng/mL | ||
| Lead | ≥70 ug/dL | Valproic acid | >121 ug/mL | ||
| Lithium | >1.5 mmol/L | Vancomycin (peak/random) | >50 ug/mL | ||
| Magnesium | <0.7 mg/dL | >6 mg/dL | Vancomycin (trough) | >25 ug/mL | |
| pH (whole blood) | <7.2 | >7.6 | Coagulation | ||
| Phenobarbital | >50 ug/mL | INR | >4.99 | ||
| Phenytoin | >30 ug/mL | Activated Partial Thromboplastin Time | >120 seconds | ||
| Phenytoin (unbound) | ≥3.0 ug/mL | Fibrinogen | <60 mg/dL | ||
| pCO2 (arterial and capillary) | >55 mmHg | Heparin level (unfractionated) | >0.99 IU/mL | ||
| Hematocrit (≥30 days old) | >66 g/dL | Hemoglobin (> 30 days old) | ≤7 g/dL | ≥20.0 g/dL | |
| Hemoglobin (0-6 days old) | ≤7 g/dL | >22.5 g/dL | Platelet Count | ≤50 K/uL | ≥1 Million K/uL |
| Hemoglobin (7--3 days old) | ≤7 g/dL | >21.5 g/dL | White Blood Cell | ≤1 K/uL | ≥40 K/uL |
| Hemoglobin (14-30 days old) | ≤7 g/dL | >20.5 g/dL | |||
| Legionella antigen | Positive | ||||
| Osmolality (Serum) | <250 mOsm/kg | >325 mOsm/kg | Ketones, Urine (<5 years old) | 5 mg/dL (Trace) | |
| Ketones, Urine (>5 years old) | >80 mg/dL | ||||
INR: Internal Normalized Ratio, BUN: Blood urea nitrogen, CK-MB: Creatine kinase myocardial band, CSF: Cerebrospinal fluid
Figure 1Geisinger new critical value process using secure text messaging
Considerations to replicate a CV system using STM
| Considerations to Replicate CV System | |||
|---|---|---|---|
| Laboratory & Staff | Hospital & Hospital Users | Technology & IT Staff | Regulatory |
| 1.) Identify key stakeholders | 1.) Identify key stakeholders | 1.) Identify key stakeholders | 1.) Examine hospital policies |
| 2.) Determine budget and perform cost analysis | 2.) Revise departmental CV as necessary | 2.) Review key computer systems and backup/downtime policies and procedures | 2.) Examine CAP CV guidelines |
| 3.) Examine current CV and revise if necessary | 3.) Revise hospital policies for cellular devices | 3.) Review access policies | 3.) Ensure compliance of CAP guidelines |
| 4.) Review and update CV notification practices and policies | 4.) Budget planning for each service line | 4.) Update phonebook and e-mail system | 4.) Perform audits to ensure continued compliance |
| 5.) Review and revise for infrastructure failures (power and internet outages, cell service disruption, etc.) | 5.) Ensure all end users are compliant | 5.) Review budget and financial planning | |
| 6.) Evaluation of STM systems | |||
| 7.) Coordinate with key stakeholders with demo of STM systems | |||
| 6.) Set goals and target dates of completion | 6.) Review and/or update policies for appropriate use of cellular devices | 8.) Select STM system | |
| 7.) Work with IT and informatics teams on system build | 7.) Review and/or update policies for access and termination of access | 9.) Develop/create interfaces between LIS, STM system, and create callback application | |
| 8.) Plan and educate laboratory staff | 8.) Create phonebook of users (if none exists) | 10.) System test prior to go-live | |
| 11.) Fix bugs/issues, and retest | |||
| 9.) Plan and education for end users | 9.) Provide feedback of program post go-live | 12.) Implement program with coordination of lab and end-users | |
| 10.) Application test prior to go-live | |||
| 11.) Post go-live analysis | 13.) Post go-live analysis | ||
| 12.) Troubleshoot as necessary | 14.) Troubleshoot as necessary | ||
Figure 2An example of our proprietary software (GML Callback) where secure text messaging critical value notifications are sent to providers
Figure 3Demonstration of critical value historical search function by patient medical record number
Figure 4Historical view of an individual critical value record that shows the critical value message, response, and time parameters
Figure 5Histogram of critical value pre- and post-implementation
The results of the provider satisfaction survey
| Survey Questions | Strongly disagree | Disagree | Undecided | Agree | Strongly agree | |
|---|---|---|---|---|---|---|
| 1.) I feel comfortable receiving Critical Values through STM. | 2 (2.5%) | 0 | 2 (2.5%) | 19 (24%) | 58 (58%) | 79 |
| 2.) Critical Value notification through STM has increased my efficiency. | 3 (2.5%) | 1 (1.25%) | 9 (11.25%) | 21 (26.25%) | 47 (58.75%) | 80 |
| 3.) I feel that receiving critical value notifications through STM is more effective than receiving a phone call. | 1 (1.25%) | 4 (5%) | 11 (1.25%) | 23 (28.75%) | 51 (63.75%) | 80 |
| 4.) I prefer to receive a phone call alerting me to a critical value than receiving it through a STM. | 44 (55%) | 30 (37.5%) | 3 (3.75%) | 2 (2.5%) | 1 (1.25%) | 80 |
| 5.) I feel I am able to provide better and faster care to patients by receiving critical values through STM. | 2 (2.47%) | 1 (1.23%) | 10 (12.35%) | 28 (34.57%) | 40 (49.38%) | 81 |
| 6.) I receive critical values through STM and frequently change patient management using our EMR application on my smart device. | 16 (19.75%) | 29 (35.80%) | 16 (19.75%) | 11 (13.58%) | 9 (11.11%) | 81 |